Investigating the link between smell and survival in glioblastoma patients
Official title: Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Run by University Hospital, Essen · NCT06954636 · Data updated 2026-11-12
This study is trying to see if the ability to smell can give us clues about how well glioblastoma patients are doing and how long they might live.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | University Hospital, Essen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Essen and 1 other locations) |
| Status | Recruiting |
| Started | May 3, 2023 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2029 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT06954636 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who have been newly diagnosed with IDH wild-type glioblastoma and have not undergone prior chemotherapy or radiotherapy.
✕Probably not a fit
Patients with neurodegenerative diseases or significant prior head or neck surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the prognostic significance of olfactory function in patients diagnosed with glioblastoma. It will assess olfactory abilities at various stages of treatment and correlate these findings with survival rates, neurocognitive performance, and quality of life. The study will involve a cohort of 64 glioblastoma patients and a control group of 64 individuals without tumor disease, utilizing olfactory tests, neurocognitive assessments, and MRI evaluations to gather comprehensive data. Additionally, molecular analyses will be conducted to investigate the relationship between olfactory function and glioblastoma characteristics.
Why it matters
Potential benefit: If successful, this study could provide a new prognostic marker for survival and quality of life in glioblastoma patients.
How similar studies have gone: While olfactory function has been studied in relation to various conditions, this specific approach in glioblastoma is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * Newly-diagnosed glioblastoma (IDH wild-type) * Never received prior chemotherapy * Never received radiotherapy to the head or neck before * KPS ≥ 70 * No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3 * No respiratory infection at the time of inclusion * No significant aphasia Exclusion Criteria: * Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome) * History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas) * Permanent olfactory impairment following infections (e.g., influenza, coronavirus) * Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia) * Language barriers likely to interfere with participation or comprehension of study procedures.
Where it's running
-
University Hospital Essen, Department of Neurology, Division of Clinical Neuro-Oncology
Essen, Germany Recruiting -
Department of Neurosurgery
Münster, Germany Recruiting
Study contacts
- Study coordinator: Christoph Oster, Dr. med.
- Email: christoph.oster@uk-essen.de
- Phone: +49201-723-82598
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TTFields with FET-PET–Guided SRS for Recurrent Glioblastoma
This trial tests whether adding FET-PET-guided stereotactic radiosurgery to TTFields helps adults with recurrent IDH-wildtype glioblastoma live longer than TTFields alone.
-
TLX101-Tx plus standard care versus standard care alone for recurrent glioblastoma
This test checks whether adding TLX101-Tx, a tumor-targeted radiopharmaceutical given with lomustine, helps adults with first-recurrence glioblastoma control their tumor or live longer compared with lomustine alone.
-
Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma
This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.
-
Evaluating CS231295 for advanced solid tumors
This study is testing a new drug called CS231295 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other treatments.
-
Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma
This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.
-
Comparing surgery and best treatment for recurrent glioblastoma
This study is testing whether surgery or the best available treatment helps people with recurring glioblastoma feel better and live longer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.